Glomerular visceral epithelial cells, also denoted as podocytes, build regularly spaced, interdigitated foot processes that form the filtration slit and are connected by a thin membrane-like slit diaphragm that has an important role in the regulation of glomerular ultrafiltration.
1,2 Damage of podocytes, which can be triggered by various factors, including oxidative and inflammatory stress, regularly leads to foot process effacement and results in a destruction of the filtration barrier and uncontrolled loss of proteins into the urinary space, which is a hallmark of many forms of kidney diseases. [1] [2] [3] [4] It was suggested that proteinuria is a result of sublytic complement C5b-9 attack on podocytes, which leads to the induction of various genes involved in the production of oxidants, proteases, and growth factors, including the transforming growth factor-b (TGFb) and the connective tissue growth factor (CTGF). 5 TGFb has an important role in many cell types. 6, 7 It initiates cellular signaling by binding to the TGFb-receptor type II, which interacts with the TGFb receptor type I (TGFbRI) and results in the activation of the kinase activity of TGFbRI. In turn, Smad proteins are phosphorylated and translocate to the nucleus to act as transcription factors. 6, 7 In the kidney, TGFb has a key effect in the induction of renal fibrosis. [8] [9] [10] Not surprisingly, in this context, TGFb is the best known stimulator of CTGF, which is considered to have a crucial role in wound repair and fibrosis, 11, 12 and is also significantly upregulated in the course of fibrotic renal disease. 13 CTGF is proposed to stimulate fibroblast proliferation, matrix production, and promote adhesion and migration of many cell types, although the detailed molecular mechanisms remain to be deciphered. such as cell proliferation and differentiation, survival, and migration. [17] [18] [19] Two subtypes of SK have been identified, SK-1 and SK-2, which are both ubiquitously expressed 20, 21 but show differential enzymatic characteristics in that SK-2 possesses a broader substrate specificity than does SK-1. 21 Total SK activity is stimulated in many cell types by various growth factors, and also by proinflammatory cytokines. Whereas the mechanism of SK-1 activation includes phosphorylation reactions, membrane translocation, 22, 23 and transcriptional events, [24] [25] [26] the mechanism of SK-2 activation is still unclear. In this study, we show that, in human podocytes, TGFb 2 not only induces the expression of profibrotic CTGF but also upregulates SK-1 activity. Depletion or inhibition of SK-1 leads to a higher CTGF expression, whereas overexpression of SK-1 causes a suppression of CTGF expression. This regulation is also observed in a mouse model of streptozotocin (STZ)-induced diabetic nephropathy, in which SK-1 and CTGF were both upregulated in podocytes under disease conditions. Strikingly, in SK-1-deficient mice, an even higher expression of CTGF was detected when compared with wild-type mice and this correlated with a deterioration of the disease.
RESULTS

TGFb 2 upregulates SK-1 activity by stimulating its gene transcription
Stimulation of human podocytes with TGFb 2 led to a concentration ( Figure 1a ) and time-dependent (Figure 1b ) increase of SK-1 protein expression, as detected by western blot analysis. The effect persisted for at least 48 h (Figure 1b) . A similar effect on SK-1 protein expression was also observed when using TGFb 1 (Figure 1c) . The increased SK-1 protein expression correlated with an increased SK-1 activity ( Figure  1d ). To discriminate the activity of SK-1 from SK-2, the composition of the in vitro kinase buffer was changed. In buffer conditions, including 1 M KCl, in which SK-1 activity is inhibited by more than 90% but SK-2 is still active, only a minor activity of SK-2 was observed (Figure 1d , triangles) . Thereafter, cell lysates were processed for western blot analysis (a-c) using specific antibodies against human SK-1 (a and c, insets, upper panels) at a dilution of 1:1000, or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (a and c, insets, lower panels) at a dilution of 1:2000. Bands corresponding to SK-1a were densitometrically evaluated and are expressed as percentage of control and means ± s. compared with SK-1 activity. This remaining SK-2 activity was not significantly altered by TGFb treatment (Figure 1d ). The upregulation of SK-1 protein expression was due to increased de-novo protein synthesis and gene transcription, as the protein synthesis inhibitor, cycloheximide, and the transcriptional inhibitor, actinomycin D, blocked TGFbtriggered SK-1 activity ( Figure 2 ) and SK-1 protein expression (Figure 2 , inset). Previously, we had shown that phorbol ester is also a potent inducer of SK-1 expression and activity in human endothelial cells 26 and mesangial cells. 27 Moreover, in podocytes, phorbol ester TPA (12-O-tetradecanoylphorbol-13-acetate) upregulated SK-1 activity ( Figure 3 ) and expression (Figure 3, inset) . Co-treatment of cells with TPA plus TGFb led to an additive effect on SK-1 activity and expression (Figure 3) , suggesting that at least two independent signaling pathways are involved in a maximal expressional upregulation of SK-1.
Moreover, TGFb 2 also upregulated SK-1, but not SK-2, mRNA expression levels, as shown by quantitative PCR analysis (Figure 4a ). To determine whether the increased SK-1 mRNA levels occurred by an increased promoter activation, 26, 28 SK-1 promoter studies were performed by using a luciferase-containing vector fused with a 2492 bp fragment of the human SK-1a promoter. Transfection of podocytes with this construct, followed by TGFb 2 stimulation, revealed a more than twofold enhancement of SK-1 promoter activity (Figure 4b To determine whether the upregulation of SK-1 by TGFb 2 has functional consequences for podocytes, a well-established TGFb-regulated target gene was investigated, that is, the CTGF, which is considered an important factor in fibrotic cell response. 13, 15, 16 The protein expression and subsequent secretion of CTGF, which was increased by TGFb (Figure 6a , open columns), were negatively regulated by SK-1, as the depletion of SK-1 by To exclude the possibility that the effects observed by siRNA transfection are due to unrelated off-target phenomena, we additionally tested a recently developed specific SK-1 enzyme inhibitor, SKI II. 29 As seen in Figure 7 , CTGF protein expression induced by TGFb was also enhanced in the presence of increasing concentrations of the inhibitor. Moreover, a stable overexpression of SK-1 in podocytes by a lentiviral transduction method resulted in a massive accumulation of SK-1a and SK-1b in the transduced cells ( Figure 8 , upper panel). In these cells, the secreted CTGF was hardly detectable (Figure 8 , lower panel), which further stresses the negative regulation of CTGF by SK-1.
In line with the negative effect of SK-1 on CTGF expression, its product S1P should reduce CTGF expression. To this end, cells were stimulated with exogenous S1P, which acted through surface S1P-receptors. However, this regimen rather stimulated CTGF expression, which was already observed at early time points of 2 h and 4 h (Figure 9a ), consistent with previous reports in other cell types.
30,31 After 24 h, CTGF expression was comparable between control-and S1P-stimulated cells ( Figure 9b ). As an intracellular way of action of S1P is also possible and has been proposed by various groups, we tested the effect of caged S1P. 32 This S1P derivative does not bind to S1P-receptors but penetrates the cells and, on illumination, the protective group is cleaved off to generate 'active' S1P in the cytoplasm. 32 Figure 9b shows that increasing concentrations of intracellularly released S1P indeed reduced CTGF expression.
SK-1 and CTGF are overexpressed in podocytes from diabetic nephropathy patients
To determine whether SK-1 is expressed in vivo in human podocytes, renal sections of healthy controls and of patients with diabetic nephropathy, according to Mogensen, 33, 34 were examined by immunohistochemical staining. SK-1 was hardly stained in podocytes of healthy samples, but in patients with diabetic nephropathy, staining was much more pronounced (Figure 10, arrowhead) . In addition, an increased CTGF expression was detected in diabetic podocytes ( Figure 10 , arrow), confirming our previous study in which we showed a coexpression of CTGF and TGF-b in podocytes of diabetic patients. 35 Thus, it is conceivable that the crosstalk between TGF-b and SK-1 signaling regulates the CTGF expression in podocytes, emphasizing the relevance of our in vitro findings for the development of renal disease.
SK-1-deficient mice develop a more severe STZ-induced nephropathy
In a further approach to address the function of SK-1 in regulating CTGF expression in vivo, STZ-mediated type 1 diabetes was induced in (C57BL/6) SK-1 þ / þ and SK-1
mice. Diabetic mice of both genotypes developed hyperglycemia with increased kidney-to-body weight ratios at day 30 compared with nondiabetic mice, with no distinguishable changes among the diabetic groups, irrespective of the SK-1 gene dose (Table 1 ). The only genotype-specific difference observed as a sign of progressive nephropathy was a sustained increase in albuminuria (Po0.05) at days 20 and 30 in (Figure 11a ). In agreement with our findings in human diabetic glomeruli, STZ-induced diabetes mellitus resulted in an enhanced protein expression of SK-1 in glomeruli, most likely located in podocytes and mesangial cells (Figure 11b , immunostaining, 30 days), and in tubules (data not shown) from SK-1 þ / þ diabetic kidneys. This increment was further confirmed by western blot for SK-1 in nondiabetic and diabetic SK-1 þ / þ kidneys (Figure 11c and d) . The specificity of SK-1-detection in mouse kidney homogenates by western blotting was confirmed by a preincubation of anti-SK-1 antibody with recombinant mouse SK-1 (Figure 11c , 'negative control'). Furthermore, by performing in situ hybridization, we detected an increased glomerular ( Figure  11e ) and tubular (data not shown) expression of CTGF mRNA in diabetic kidneys from mice of both genotypes. However, SK-1 deficiency markedly enhanced CTGF mRNA expression in podocytes, as shown by in situ hybridization ( Figure 11e ) and its semi-quantification (Figure 11f ).
DISCUSSION
In this study, we have shown that in vitro TGFb 2 potently upregulates SK-1 expression and activity in glomerular podocytes. In vivo, SK-1 is highly upregulated in podocytes of kidneys from diabetic nephropathy patients, as well as in kidneys from mice with STZ-induced nephropathy. We show for the first time that, mechanistically, TGFb upregulated SK-1 expression by stimulating the SK-1 promoter activity (Figure 4b ). Promoter sequence analyses revealed two putative Smad-binding elements, one Smad-3 and one Smad-4-binding site (see Figure 4a) . By site-directed mutagenesis of these two sites, we identified the Smad-4-binding site as a functional site responsible for the TGFbtriggered effect. Previously, it was shown that Sp1 and AP-2 sites were involved in phorbol ester-induced SK-1 promoter activation in the leukemia cell line, MEG-O1. 36 In addition, we recently identified a functional hypoxia-responsive element that mediates hypoxia-triggered SK-1 upregulation in human endothelial cells, 37 and a STAT5-binding site that mediates prolactin-triggered SK-1 upregulation in the human breast cancer cell line, MCF7. 28 All these data underline that SK-1 activity is tightly regulated by transcriptional mechanisms. Obviously, the TGFb/Smad signaling cascade represents one possible mode of upregulation of SK-1 expression and activity, whereas phorbol ester-activated PKC signaling is a further separate mode of SK-1 expression and activation. In combination, TGFb plus phorbol ester exerted an additive effect on SK-1, as one expects from independent signaling pathways acting on the same cell response. Together, this suggests that for a full persistent activation of SK-1, activation of both the PKC and Smad signaling modules is required. A similar upregulation of SK-1 mRNA and activity by TGFb was also reported for dermal fibroblasts, although the mechanism was not further addressed. 38 In functional terms, our data show that the activation of SK-1 by TGFb is involved in the regulation of the important profibrotic factor, CTGF. CTGF is upregulated in most fibrotic diseases, including human crescentic glomerulonephritis 39 and experimental proliferative glomerulonephritis. 40 In view of these data, SK-1 may act as a brake in a fibrotic event by impeding CTGF expression. This is further supported by our in vivo model showing that SK-1-deficient mice not only express higher amounts of CTGF but also develop a more severe diabetic nephropathy when treated with STZ and compared with SK-1 wild-type mice.
Most notably, we found that the suppressive effect of SK-1 is exclusively mediated by locally generated intracellular S1P, and not by extracellular S1P acting through S1P-receptors. In fact, extracellular S1P even has an opposite effect and can increase CTGF expression and may thereby even worsen a fibrotic process. The mechanisms by which intracellular S1P suppresses CTGF protein expression remain unknown, because the identity of intracellular S1P targets is still not defined. Various studies have shown that intracellular S1P triggers an intracellular Ca 2 þ mobilization, which occurs independently of a phospholipase C/IP 3 -driven Ca 2 þ release. 41 Thus, it is tempting to speculate that Ca 2 þ channels are directly affected by intracellular S1P.
Inhibition of SK-1 has been proposed as a useful approach to treat tumor growth, as shown in a mouse xenograft model. 29, 42 Additional in vivo effects of these SK-1 inhibitors have not yet been addressed. Our data show that SK-1 inhibition also results in an increased CTGF expression in kidney cells and this could lead to adverse side effects when using SK-1 inhibitors in vivo. However, it should be noted that the relation of CTGF with tumor development and growth is still controversial. On the one side, a reduced CTGF expression was reported for various tumors, including lung cancer, 43 leading to speculations that CTGF could be a tumor suppressor. Consistent with this idea, increased CTGF levels were shown to inhibit the metastatic activity of human lung cancer cells. 44, 45 Most recently, it was shown that CTGF levels were decreased in Wilms tumor (nephroblastoma), 46 and that recombinant CTGF inhibited the proliferation of a Wilms tumor cell line. On the other side, CTGF was proposed to promote angiogenesis 47 and tumorigenesis of prostate cancer cells. 48 Moreover, blocking CTGF action by a recently developed neutralizing antibody, FG-3019, inhibited pancreatic tumor growth and metastasis. 49, 50 Overall, these data raise the question whether inhibition of SK-1 could have a beneficial or deteriorating effect on renal fibrotic diseases. In this context, it has previously been reported that STZinduced diabetic nephropathy in rats correlated with an accumulation of S1P in glomeruli isolated from kidney cortex. 51 Moreover, high glucose conditions led to an increased SK-1 activity in endothelial cells 52 and in vascular smooth muscle cells, 53 proposing a role for SK-1 in diabetic vasculo-and nephropathies. However, these studies did not address whether SK-1 positively promotes diabetic nephropathy or whether SK-1 is induced as a rescue mechanism to counter-regulate disease progression. Recently, Kono et al. 54 reported that SK-1 is upregulated in fibrotic foci in a mouse Co S1P
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Co S1P Figure 9 | Effects of exogenously applied S1P and intracellularly generated S1P on connective tissue growth factor (CTGF) expression. (a) Podocytes were stimulated for 2 h and 4 h with either vehicle (Co) or 3 mM of exogenous S1P.
(b) Cells were stimulated for 24 h with either vehicle (Co), 3 mM of exogenous S1P, or 3 mM and 10 mM of caged S1P (illuminated for 30 s at 360 nM and with a change of medium before stimulation). Thereafter, supernatants were taken for protein precipitation using trichloroacetic acid and for the determination of secreted CTGF protein (upper panels) by western blot analysis using an antibody against CTGF at a dilution of 1:1000. The corresponding cell lysates were taken for GAPDH analysis (lower panels). Data are representative of four independent experiments giving similar results.
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Control Diabetic nephropathy Negative control 50 μm 100 μm Figure 10 | Immunohistochemical staining of SK-1 in kidney sections from patients with diabetic nephropathy. Glomerular SK-1 and connective tissue growth factor (CTGF) expression in normal human kidney (control, left panels) and in kidneys from patients with manifest diabetic nephropathy (middle panels) were detected by immunohistochemical staining using an anti-SK-1 antibody as described in the Materials and Methods. The arrowhead points to SK-1 expression and the arrow points to CTGF expression in podocytes. Renal sections from patients with diabetic nephropathy were used as negative controls by omitting the primary antibody (right panels). Bars indicate magnification.
model of pulmonary fibrosis, although no SK-1 À/À mice were used in that study to prove the in vivo contribution of SK-1 to the disease. Our studies using SK-1 À/À mice now suggest that SK-1 induced under disease conditions exerts a protective function and its depletion results in a more severe kidney disease.
In summary, our data have shown that in human podocytes, TGFb potently upregulates SK-1 expression and activity, which critically contributes to a negative regulation of CTGF expression, which exerts a key effect in organ fibrosis. Furthermore, the in vivo model of STZ-induced diabetic nephropathy showed that SK-1 exerted a protective function, as SK-1 À/À mice developed a more severe disease that correlated with an enhanced CTGF expression. However, this study leaves open tantalizing questions with regard to extracellular and intracellular S1P and whether inhibition of SK-1 in vivo is a good or bad effect. This thrilling question definitely needs to be addressed in future studies.
MATERIALS AND METHODS Chemicals TGF-b was obtained from R&D Systems (Wiesbaden, Germany); cycloheximide, actinomycin D, and STZ were purchased from Sigma-Aldrich Fine Chemicals (Deisenhofen, Germany); and all inhibitors were obtained from Merck Biosciences (Schwalbach, Germany). The CTGF (L-20) antibody, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (V-18) antibody, and the human Smad-4 siRNA (sc-29484) were purchased from Santa Cruz Biotechnology (Heidelberg, Germany); the SK-1-specific antibody was generated and characterized as previously described. 25, 26 Cell culture A human immortalized podocyte cell line was cultured as described. 55 Cells were normally cultured at 33 1C. For experiments, cells were cultured at 37 1C for a further 10 days. These cells were characterized by the expression of the podocyte-specific protein, nephrin. 1, 55 For synchronization, cells were incubated for 16 h in Dulbecco's modified Eagle's medium, including 0.1 mg/ml of fatty acid-free bovine serum albumin.
siRNA transfections
Gene silencing of human SK-1 was performed exactly as previously described. 26, 28 Silencing efficiency was confirmed by western blot analysis.
Quantitative PCR analysis Real-time PCR was performed using a BioRad iQ-iCycler Detection System (BioRad, München, Germany). Primer sequences were as follows: human GAPDH (accession number: NM_002046): forward: GCTCTCTGCTCCTCCTGTTC; reverse: CGCCCAATACGACCAA ATCC; human SK-1 (accession number: NM_021972): forward: GGGCTTCATTGCTGATGTGGAC; reverse: TGCCTGCCATTACAA CTGTCC; IQ5 Optical System Software (version 2.0, BioRad) was used to analyze real-time and end point fluorescence.
Western blot analysis Stimulated cells were homogenized in lysis buffer and processed as previously described. 25, 26 Protein of 30 mg was separated on sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane, and subjected to western blot analysis. To prove that the anti-human SK-1 antibody also specifically recognized mouse SK-1 in mouse kidney homogenates, the antibody was preincubated with recombinant mouse SK-1a (SPHK1a, Biomol, Hamburg, Germany) for 12 h at 4 1C before an overnight incubation at 4 1C with the western blot of nondiabetic and diabetic homogenates of SK-1 þ / þ kidneys.
SK activity assay
In vitro kinase reactions were performed exactly as previously described. 26 For SK-1 activity, 0.5% Triton X100 was included to block SK-2 activity. 21 For SK-2 activity, 1 M KCl was included to block SK-1 activity. 21 
SK-1 promoter studies
A 2492 bp fragment of the human SK-1a promoter was cloned by reverse transcriptase PCR using the following primers: forward with an Nhe1 side: GCTAGCAGGTGCAGGACCCATCATTC; reverse with a HindIII side: AAGCTTCCTGCCTTCAGCTCCTTATC. The promoter fragments were fused into the pGL3 luciferase reporter genecontaining vector (Promega, Mannheim, Germany). Cell transfections and reporter assays were performed exactly as described. 26 Values for relative SK-1 promoter activities were calculated from the ratio of firefly/Renilla luciferase activities.
Promoter mutations
All mutated constructs were generated using the QuickChange SiteDirected Mutagenesis Kit (Stratagene, La Jolla, CA, USA) using the following mutation primers: for pGL-hSK1a-DSmad3: forward: GCCGCCTTCTAGCCAACTGCCTAGGACGAGCGGC (GAC to ACT); for pGL-hSK1a-DSmad4: forward: TGGGCGGCGGGCGTTT CGCCCCGGCCTGGAGA (GAG to TTT). The mutated sites were verified by sequencing.
Tissues for histological investigations
For controls, tumor-free kidney samples were obtained from six patients undergoing nephrectomy for renal carcinoma. Diabetic changes were examined in tissues from two kidney biopsies with no evidence of malignancy and in six tumor-free samples from carcinoma kidneys from patients with manifest diabetic nephropathy. The clinical data of these patients have been described previously. 35, 56 The study was approved by the Ethical Committee of the Medical Faculty, University of Muenster. þ / þ and SK-1 À/À kidneys after 30 days of STZ diabetes and (f) its semi-quantification expressed as the ratio (%) of the glomerular CTGF mRNA-positive area to the whole glomerular area from 10 randomly selected high-power fields. Arrows indicate expression of CTGF in podocytes. Bars indicate magnification. The asterisk between bars indicates statistical differences between diabetic and nondiabetic SK-1 þ / þ kidneys, Tissue samples were fixed and prepared as previously described. 56 Paraffin sections (2-6 mm) were stained using periodic acid-Schiff reagent to ascertain the absence of tumor infiltration and were processed for immunohistochemistry using a rabbit antihuman SK-1 antibody at a dilution of 1:500 and a secondary alkaline phosphatase-coupled anti-rabbit antibody. Counterstaining was performed using Mayer's hemalaun. For mouse tissue, serial sections (3-5 mm) of paraffin-embedded mouse kidney samples were used. Counterstaining was performed using methyl green. The specificity of staining was ascertained using negative controls by omitting the primary antibody and by using non-immune serum 'unspecific' IgG.
In situ hybridization in mouse kidney A DNA probe comprising nucleotides 1-492 of mouse CTGF cDNA was used for in situ hybridization of formaldehyde-fixed and RNAse-free paraffin-embedded kidney sections as described previously. 56 To semi-quantify the expression of CTGF, 10 randomly selected nonoverlapping fields of the renal cortex were examined under high-power-field magnification and the ratio (%) of the glomerular CTGF-mRNA-positive area to the whole glomerular area was determined using the Soft Imaging System (Olympus, Tokyo, Japan). Mean values of at least five kidneys per group were averaged.
Animal experiments
All animal experiments were conducted in accordance with the German Animal Protection Law and were approved by the Ethics Review Committee of the District Governments of Muenster and Darmstadt, Germany. To induce type-1 diabetes, 2-month-old male SK-1 þ / þ (C57BL/6) and SK-1 À/À mice 57 were intraperitoneally injected with STZ (45 mg/kg of body weight) dissolved in 100 mM sodium citrate buffer (pH 4.5) for four consecutive days. Control animals were injected with citrate buffer. Mice that had developed glycosuria received a subcutaneous insulin implant (Linplant À ) (Linshin, Ontario, Canada) to prevent ketoacidosis. Blood glucose levels were controlled every 10 days (Haemo-Glukotest; Roche Diagnostics, Mannheim, Germany). Urinary glucose and ketones were measured using reagent strips (Keto-Diastix Reagent Strips, Bayer Vital, Leverkusen, Germany). Urinary creatinine excretion was determined with the Creatinine Assay Kit (NatuTec, Frankfurt/Main, Germany), and the Albuwell M ELISA Kit (Exocell, Philadelphia, PA, USA) was used for quantification of urinary albumin excretion. Kidneys (n ¼ 6 per group) were harvested and analyzed 30 days after induction of diabetes.
Statistical analysis
Statistical analysis was performed using one-way analysis of variance, followed by Bonferroni's post hoc test for multiple comparisons.
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